OHKI HEALTHCARE HOLDINGS CO.,LTD.

Business Details

The Group is an intermediary distribution business focused on the healthcare category, comprising pharmaceuticals, health foods, cosmetics, sanitary products, and daily sundries. Centered on its core subsidiary Ohki Co., Ltd., the Group operates a "demand-creation" model that surfaces latent consumer demand through partnerships with retailers and manufacturers. Major customers include Amazon Japan G.K. and Sugi Pharmacy Co., Ltd. The company is pursuing strengthened non-price competitiveness by increasing the sales mix of distribution-exclusive products, and is promoting operational efficiency through digitization and electronic systems.

Recent Overview

Sales increased but operating profit fell sharply by 74%; no earnings forecast disclosed for next fiscal year

In FY2026 (ending March 2026), net sales increased to ¥360,358 million (up 3.1% year on year), but operating profit fell sharply to ¥719 million (down 74.0% year on year) and ordinary profit declined to ¥1,964 million (down 50.8% year on year). Contributing factors included revised trading terms resulting from consolidation among major retailers, delayed pass-through of price increases, continued rises in personnel and logistics costs, increased upfront investment burden from digitization and system development, temporary costs associated with relocating head office functions, and inventory disposal at a subsidiary. Selling, general and administrative expenses expanded to ¥16,899 million (up 7.4% year on year), growing at a pace exceeding gross profit of ¥17,619 million (down 4.8% year on year). The earnings forecast for FY2027 (ending March 2027) was not disclosed, citing surging raw material and transportation costs and procurement instability stemming from turmoil in the Middle East. A dividend of ¥30 per share was paid (an increase of ¥4 year on year).

Key Products

Growth Drivers

• Strengthening non-price competitiveness by increasing the sales mix of distribution-exclusive products
• Capturing demand for pharmaceuticals, health foods, and cosmetics amid rising inbound tourism demand
• Surfacing latent demand through new category proposals and support for new product development (demand-creation model)
• Improving efficiency and reducing costs in indirect operations, including logistics, through digitization and electronic systems
• Supporting sales promotion and strengthening in-store sales capabilities through collaboration with investees and business partners
• Improvement in net assets and equity ratio driven by a ¥2,171 million increase in valuation difference on available-for-sale securities

Risks

• Pressure on SG&A expenses from continued rises in personnel and logistics costs and upfront investment in digitization and systemization (FY2026 (ending March 2026) SG&A expenses of ¥16,899 million, up 7.4% year on year)
• Strengthened price negotiating power and rising center fees from consolidation among major retailers, along with revisions to trading terms
• Surging raw material, materials, and transportation costs and unstable procurement stemming from turmoil in the Middle East (the main reason for non-disclosure of the FY2027 (ending March 2027) earnings forecast)
• Decline in gross margin due to delayed pass-through of price increases (FY2026 (ending March 2026) gross margin of 4.89%, down from 5.30% in the prior year)
• Long-term decline in domestic aggregate demand and slowing healthcare demand due to population decline
• Credit risk from deteriorating financial condition of business partners (¥194 million in provision for doubtful accounts recorded as extraordinary loss in FY2026 (ending March 2026))
• Continued negative operating cash flow (¥-1,415 million in FY2026 (ending March 2026)) and low level of cash and cash equivalents (period-end balance of ¥2,213 million)